You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 1
  • 02.01 Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumour necrosis factor inhibitors: A systematic review and meta-analysis

Article metrics

Article menu
Download PDFPDF
New players and novel targets in inflammation
02.01 Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumour necrosis factor inhibitors: A systematic review and meta-analysis

 

Online download statistics by month:

Online download statistics by month: March 2017 to March 2024

AbstractFullPdf
Mar 2017604
May 20174209
Jun 20172106
Jul 20172604
Aug 20172201
Sep 20172205
Oct 20171803
Nov 20171001
Dec 20172804
Jan 20182404
Feb 20183001
Mar 20183202
Apr 20181201
May 20181000
Jun 20181801
Jul 20181200
Aug 2018800
Sep 20181001
Oct 20182401
Nov 20181200
Dec 20181801
Jan 20191600
Feb 2019400
Mar 2019801
Apr 20192600
May 20193000
Jun 2019900
Jul 20193200
Aug 20193000
Sep 20191600
Oct 20192100
Nov 20191200
Dec 2019400
Jan 20204202
Feb 20201200
Mar 20201400
Apr 20201100
May 20201701
Jun 2020600
Jul 20201000
Aug 2020600
Sep 20201000
Oct 20201500
Nov 2020901
Dec 2020800
Jan 2021900
Feb 2021200
Mar 2021400
Apr 20211000
Sep 2021001
Oct 2021300
Nov 2021201
Dec 2021800
Jan 20223800
Feb 2022801
Mar 2022700
Apr 2022400
May 2022801
Jun 2022600
Jul 2022600
Aug 20221101
Sep 20221200
Oct 2022700
Nov 2022200
Dec 2022400
Jan 2023500
Feb 2023200
Mar 20231100
Apr 20231000
May 20231100
Jun 20231200
Jul 2023400
Aug 2023200
Sep 20231601
Oct 2023201
Nov 2023200
Dec 2023300
Feb 20242300
Mar 2024500
Total1032061